Kairos Pharma, LTD. 8-K

What Happened
Kairos Pharma, Ltd. (KAPA) announced on June 4, 2026 that it issued a press release summarizing the company’s achievements in the first half of 2026 and outlining key milestones it expects to reach by the end of 2026. The press release was furnished as Exhibit 99.1 to the Form 8‑K; the company specified the furnished information is not being “filed” under Section 18 of the Exchange Act and is not incorporated by reference into other filings.

Key Details

• Press release dated June 4, 2026 was furnished with the Form 8‑K (Exhibit 99.1).
• Content covers H1 2026 operational achievements and lists expected milestones through year‑end 2026.
• The company explicitly stated the Form 8‑K information is furnished (not filed) and not automatically incorporated by reference into future SEC filings.

Why It Matters
This filing provides an operational update and a roadmap of near‑term milestones that may contain company catalysts (e.g., clinical, regulatory, or program updates). Because the information is furnished rather than filed, it conveys the company’s public progress but does not carry the same legal filing status as formal SEC-filed financial reports or proxy statements. Investors should read the June 4 press release for specifics on programs and timelines and watch for subsequent SEC filings or company releases for formal disclosures of results or material developments.